Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Public ClinicalTrials.gov record NCT07352566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Utilization of a Cutaneous Therapy In Situ Microdevice
Study identification
- NCT ID
- NCT07352566
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- University of California, San Francisco
- Other
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- 5-Fluorouracil Drug
- Abrocitinib Drug
- Adalimumab Drug
- Apremilast Drug
- Azathioprine Drug
- Baractinib Drug
- Bimekizumab Drug
- Calcipotriene Drug
- Certolizumab Drug
- Chloroquine Drug
- Crisaborole Drug
- Cyclosporine Drug
- Deucravacitinib Drug
- Dupilumab Drug
- Etanercept Drug
- Guselkumab Drug
- Hydroxychloroquine Drug
- In situ cutaneous microdevice Device
- Infliximab Drug
- Ixekizumab Drug
- Lebrikizumab Drug
- Methotrexate Drug
- Mycophenolate Drug
- Nemolizumab Drug
- Risankizumab Drug
- Roflumilast Drug
- Ruxolitinib Drug
- Secukinumab Drug
- Tacrolimus Drug
- Tapinarof Drug
- Tildrakizumab Drug
- Tofacitinib Drug
- Tralokinumab Drug
- Triamcinolone Drug
- Upadacitinib Drug
- Ustekinumab Drug
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2025
- Primary completion
- May 31, 2030
- Completion
- May 31, 2030
- Last update posted
- Jan 19, 2026
2026 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94158 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07352566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07352566 live on ClinicalTrials.gov.